

# DISCIPLINED CAPITAL ALLOCATION, POSITIONED FOR STRATEGIC GROWTH

CSE: CL  
OTC: CRLBF

FOURTH QUARTER 2025  
MARCH 5, 2026

**CRESCOLABS®**

LIQUID LIVE RESIN

**SUPERIOR BY  
NATURE**



# DISCLAIMER

## Forward-Looking Information and Statements

This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the control of Cresco Labs Inc. (“Cresco Labs”), including statements regarding Cresco Labs’ expected financial performance, the current and projected market and growth opportunities for the company, and the timing and completion of announced acquisitions, including all required conditions thereto. Often, but not always, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. Forward-looking statements and information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cresco Labs or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks contained in the public filings of Cresco Labs filed with Canadian securities regulators and available under Cresco Labs’ profile on SEDAR at [www.sedar.com](http://www.sedar.com), including the information under the heading “Risk Factors” in Cresco Labs’ annual information form for the year ended December 31, 2025, and with the United States Securities and Exchange Commission (the “SEC”) through EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar), including Cresco Labs’ annual report on Form 40-F for the year ended December 31, 2025; and other factors, many of which are beyond the control of Cresco Labs.

In respect of the forward-looking statements, Cresco Labs has provided certain statements and information in reliance on certain assumptions that it believes reasonable at this time. Although Cresco Labs believes that the assumptions and factors used in preparing the forward-looking information or statements in this presentation are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Cresco Labs has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this presentation are made as of the date of this presentation and Cresco Labs does not undertake any obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

## Non-GAAP Financial Measures

This presentation reports its financial results in accordance with U.S. GAAP and includes certain non-GAAP financial measures that do not have standardized definitions under U.S. GAAP. The non-GAAP measures include: Earnings before interest, taxes, depreciation and amortization (“EBITDA”); Adjusted EBITDA; Adjusted EBITDA margin; Adjusted gross profit; Adjusted gross profit margin; Adjusted selling, general and administrative expenses (“Adjusted SG&A”), Adjusted SG&A margin; and Free Cash Flow are non-GAAP financial measures and do not have standardized definitions under U.S. GAAP. The Company defines these non-GAAP financial measures as follows: EBITDA as net loss (income) before interest, taxes, depreciation and amortization; Adjusted EBITDA as EBITDA less other (expense) income, net, fair value mark-up for acquired inventory, adjustments for acquisition and non-core costs, impairment and share-based compensation; Adjusted EBITDA Margin as Adjusted EBITDA divided by revenues, net; Adjusted gross profit as gross profit less fair value mark-up for acquired inventory and adjustments for acquisition and non-core costs; Adjusted gross profit margin as Adjusted gross profit divided by revenues, net; Adjusted SG&A as SG&A less adjustments for acquisition and non-core costs; Adjusted SG&A margin as Adjusted SG&A divided by revenues, net; and Free Cash Flow as Net cash provided by operating activities less purchases of property and equipment and proceeds from tenant improvement allowances. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

# CRESCO LABS AT-A-GLANCE

Leading Wholesaler of Branded Cannabis Products and Highly Productive Dispensaries

## WHOLESALE

Leading Portfolio of Brands

#1 Market Share in Multiple Billion Dollar Markets<sup>1</sup>


Investing in Exclusive Genetics, Technology and Automation

## RETAIL

73 Operating Stores<sup>2</sup>

Retail Network Outperforms Fair Share<sup>3</sup>

Proprietary Retail E-comm Platform and Loyalty Program Delivering Growth



(1) Based on Q4 2025 Hoodie Data  
(2) As of December 31<sup>st</sup>, 2025  
(3) Based on internal and state data

# 2025 GROWTH PRIORITIES

Creating the **Strongest and Most Valuable** Cresco Labs

STRATEGIC  
FOOTPRINT GROWTH

**Maximize core  
& new market  
opportunities**

HIGHLY  
PRODUCTIVE RETAIL

**Expand  
retail network  
& efficiency**

EXPANSION  
BEYOND THE CORE

**Expand into  
new growth  
platforms**

# KEY METRICS, Q4 2025

(\$ in millions)

<b>Total Revenue</b>	<b>\$161.6</b>
<i>Q3 to Q4 % Growth / (Decline)</i>	<i>(2.0%)</i>
<b>Adj. Gross Profit</b>	<b>\$84.4</b>
<i>Adj. Gross Margin</i>	<i>52.2%</i>
<b>Adj. EBITDA</b>	<b>\$40.4</b>
<i>Adj. EBITDA Margin</i>	<i>25.0%</i>
<b>Operating Cash Flow</b>	<b>\$27.4</b>
<b>Free Cash Flow</b>	<b>\$18.4</b>
<b>Leverage</b> <i>Annualized Debt to Adj. EBITDA</i>	<b>3.10x</b>

# Q4 2025 RESULTS

**Flexibility and financial strength** needed to navigate market volatility as we prepare **to invest thoughtfully for long-term growth**



**Topline Revenue of \$162 Million**, strong brand performance and retail productivity helping to offset price compression



**Refinanced Senior Secured Loan** pushed back maturity date to 2030



**Q4 Free Cash Flows of \$18 Million** while continuing to invest in wholesale and retail capabilities and sustained innovation.


# PRIORITIZING CASH GENERATION

Improving Efficiency and Cashflow, Redeploying Capital with Better Paybacks and Higher Returns

Generated ~\$73 million in operating cash flow in 2025 paid down ~\$35 million in debt and ended the year with ~\$94 million in cash and cash equivalents (incl. restricted cash).

Refinanced senior secured loan with a new **\$325 million credit facility** maturing in 2030 – leaving Cresco Labs with no near-term debt maturities.

# ANNUAL OPERATING CASH FLOW



# WHOLESALER & DISTRIBUTOR OF AMERICA'S LEADING CANNABIS BRANDS



## 13 Production Sites

1 million total cultivation facility square footage



## #1 Market Share

in multiple \$1 billion+ markets

# PROVEN DEPTH IN WHOLESALE

Winning with **Quality Products** and **Innovative Infusion**

	FLOWER	VAPES	CONCENTRATES	EDIBLES	MEDICINALS
BEST	 FLORACAL™	 FLORACAL™	 FLORACAL™	 FLORACAL™  MINDY'S™ <small>— WORLD'S BEST TASTING EDIBLES —</small>	
BETTER	CRESCO	CRESCO	CRESCO	GOOD NEWS™	 Remedi™
GOOD	<u>HIGH SUPPLY™</u>	GOOD NEWS™ <u>HIGH SUPPLY™</u>	<u>HIGH SUPPLY™</u>	 wonder™	



CRESCOLABS®

# HIGHLY PRODUCTIVE RETAILER



**73 Operating Retail Locations**

As of December 31, 2025



**Outperforming Fair Share**

30% more productive than the average store  
across our footprint


Sunnyside\*



CRESCOLABS®

# SUNNYSIDE.SHOP

An E-Commerce Platform Unlike Any Other – Unparalleled Proprietary Capabilities, Insights and Experience



## CUSTOMER SERVICE

4.9

*Average Google review across Sunnyside\**

## CUSTOMER RETENTION

63%

*of Q3 2025 Customers  
Returned in Q4 2025*

# STATE-BY-STATE ASSET SUMMARY

**Strong Positions in Markets That Matter** – Driving Share Leadership Today and Capturing Growth of Tomorrow

<i>As of December 31, 2025</i>		FL	IL	KY	MA	MI	NY	OH	PA	TOTAL
Population	<i>#M</i>	23.8	12.8	4.6	7.2	10.1	19.9	11.9	13.1	<b>103.4</b>
Legal Status	<i>AU / M</i>	M	Both	M	Both	Both	Both <sup>1</sup>	Both	M	<b>5   AU+M 3   M</b>
2026E Market Size	<i>\$B</i>	\$1.7	\$1.5	\$0.0	\$1.8	\$3.0	\$2.1	\$1.3	\$1.2	<b>\$12.6</b>
Operational Dispensaries	<i>#</i>	31	10	--	4	--	3	6	18	<b>73</b>
Dispensary Licenses	<i>#</i>	30+ <sup>2</sup>	10	--	4	--	4	8 <sup>3</sup>	18	<b>74+</b>

Source: Company Reports, BDSA, U.S. Census

<sup>1</sup>Adult-Use Cannabis Approved; However, Company AU Sales Have Not Commenced

<sup>2</sup>Unlimited Licenses

<sup>3</sup>Allowable Under Adult-use program

# FINANCIAL RESULTS

CRESCOLABS®

# FINANCIAL HIGHLIGHTS

## Capitalization Summary

### SHARES OUTSTANDING

Share Class (# in millions)	as of 12/31/2025
Super Voting Shares	0.5
Redeemable Units	85.3
Subordinated Voting Shares	343.2
Proportionate Voting Shares (as converted)	16.3
Dilutive Securities (including all Options, RSUs)	39.5
<b>Total Fully Diluted Shares Outstanding</b>	<b>484.3</b>

### NET DEBT

Balance (\$ in Millions)	as of 12/31/2025
Debt Outstanding (ST)	\$10.8
Debt Outstanding (LT)	417.1
Long-term Leases	144.0
<b>Total Debt</b>	<b>\$571.9</b>
Cash and Equivalents (incl. restricted cash)	94.3
<b>Net Debt</b>	<b>\$477.6</b>



Tables may not add due to rounding  
Fully Diluted Shares Outstanding does not include Super Voting Shares

# FINANCIAL HIGHLIGHTS

## Reconciliation of Non-GAAP Measures

### ADJUSTED GROSS PROFIT

For the Three Months Ending December 31 (\$ in Millions)	Q4 2025	Q4 2024
<b>Revenue, net</b>	<b>\$161.6</b>	<b>\$175.9</b>
Cost of goods sold (COGS)	78.2	91.9
<b>Gross profit</b>	<b>83.3</b>	<b>84.0</b>
Fair value mark-up for acquired inventory	0.0	0.0
COGS adjustments for acquisition and other non-core costs	1.0	3.1
<b>Adjusted gross profit (Non-GAAP)</b>	<b>\$84.4</b>	<b>\$87.1</b>
Adjusted gross profit % (Non-GAAP)	52.2%	49.5%

### ADJUSTED EBITDA

For the Three Months Ending December 31 (\$ in Millions)	Q4 2025	Q4 2024
Net income (loss)	(\$88.9)	\$0.4
Depreciation and amortization	10.8	13.9
Interest expense, net	14.3	13.2
Income tax expense	1.8	2.6
<b>EBITDA (Non-GAAP)</b>	<b>(\$62.1)</b>	<b>\$30.2</b>
Other expense (income), net	(2.7)	3.2
Fair value mark-up for acquired inventory	0.0	0.0
Adj. for acquisitions other non-core costs	8.1	4.5
Impairment loss	93.5	0.0
Share-based compensation	3.7	3.7
<b>Adjusted EBITDA (Non-GAAP)</b>	<b>\$40.4</b>	<b>\$41.5</b>
Adjusted EBITDA %	25.0%	23.6%



Tables may not add due to rounding

# FINANCIAL HIGHLIGHTS

## Reconciliation of Non-GAAP Measures

### ADJUSTED SG&A

For the Three Months Ending December 31 (\$ in Millions)	Q4 2025	Q4 2024
Selling, general and administrative	\$57.0	\$56.0
Adjustments for acquisition and other non-core costs	7.7	2.3
<b>Adjusted SG&amp;A (Non-GAAP)</b>	<b>\$49.3</b>	<b>\$53.7</b>
Adjusted SG&A % (Non-GAAP)	30.5%	30.5%

### FREE CASH FLOW

For the Three Months Ending December 31 (\$ in Millions)	Q4 2025	Q4 2024
Net cash provided by (used in) operating activities	\$27.4	\$29.5
Purchases of property and equipment	(9.0)	(3.2)
Proceeds from tenant improvement allowances	0.0	0.4
<b>Free Cash Flow (Non-GAAP)</b>	<b>\$18.4</b>	<b>\$26.7</b>



# THANK YOU

INVESTORS

[investors@crescolabs.com](mailto:investors@crescolabs.com)

MEDIA

[press@crescolabs.com](mailto:press@crescolabs.com)

GENERAL INQUIRIES

312-929-0993

[info@crescolabs.com](mailto:info@crescolabs.com)

**CRESCO**  
LABS™

